Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
A legfontosabb adatok
- Ki végzi
- Biohaven Therapeutics Ltd.
- Hol
- Albuquerque, Amarillo, Asheville, Atlanta, Baton Rouge, Burbank, Canton, Champaign, Chattanooga, Cincinnati, Dallas, Denton, Doral, El Paso, Farmington Hills, Fayetteville, Fort Myers, Greenville, Hialeah, Hollywood, Houston, Huntington Beach, Kansas City, La Jolla, Las Vegas, Layton, Lenexa, McKinney, Memphis, Miami, Midlothian, Morehead City, Norman, North Charleston, Oak Brook, Oakland, Orchard Park, Palm Beach Gardens, Philadelphia, Raleigh, San Antonio, San Diego, Seattle, Shavano Park, South Gate, Springfield, St Louis, Statesville, Tampa, Tucson, Walnut Creek, Washington D.C., Weslaco és Wilmington (Egyesült Államok)Mind a 57 helyszín megnézéseMég 2 másik országban, 6 helyszínen
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 300 fő, tervezett
- Kezdés
- 2026. jún. 26.
- Várható befejezés
- 2028. febr.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- BHV-1300
- Placebo
- A regiszteradat frissítve
- 2026. november 12.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with Graves' disease who currently have an overactive thyroid (hyperthyroidism).
- Életkor
- 18 Years to 70 Years
- Nem
- All sexes can join.
- A betegség stádiuma
- Active hyperthyroidism caused by Graves' disease.
- Korábbi kezelés
- People who had radioactive iodine or thyroid surgery cannot join. People who took levothyroxine, desiccated thyroid extract or T3 within six weeks of the Baseline/Day 1 Visit cannot join.
- Biomarker vagy leletérték
- Graves' disease confirmed by a blood test showing raised autoantibodies.
A részvétel fő kizáró okai
- Overactive thyroid from another cause, such as toxic adenoma or toxic multinodular goiter
- Thyroid storm (a severe, life-threatening thyroid flare) within 6 weeks of Screening
- Another autoimmune disease that needs treatment
- Moderate to severe thyroid eye disease (TED), or planned surgery, radiation or medical treatment for TED
- Expected need for urgent thyroid surgery or ablation within six weeks of Baseline/Day 1 or during the study
A regiszter feltételei, szó szerint
Mind a 9 feltétel megnézéseKevesebb
Ki vehet részt
- Participants must have serologically confirmed Graves' disease as documented by presence of elevated autoantibodies
- Participants must have active hyperthyroidism due to Graves' disease
Ki nem vehet részt
- History of treatment with radioactive iodine or thyroid surgery
- Have received levothyroxine, desiccated thyroid extract, or T3 at any dose within six weeks of the Baseline/Day 1 Visit
- Are expected to require urgent or emergent thyroid surgery or ablation within six weeks of Baseline/Day 1 or throughout the study
- History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter)
- Thyroid storm, i.e. severe thyrotoxicosis with evidence of systemic decompensation (e.g., Burch-Wartkofsky Point Scale of ≥ 45 or Japanese Thyroid Association category 1 or 2, with accompanying manifestations including hyperpyrexia, tachycardia, arrhythmias, congestive heart failure, agitation, delirium, psychosis, stupor, and coma, as well as nausea, vomiting, diarrhea, or hepatic failure) within 6 weeks of Screening
- Have autoimmune disease other than Graves' disease requiring treatment
- Have moderate to severe thyroid eye disease (TED) or are expected to require immediate surgical intervention and/or are planning corrective surgery/irradiation or medical therapy for TED during study participation
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 70 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
Még 2 másik országban, 6 helyszínen
- Albuquerque, New MexicoHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Amarillo, TexasHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Asheville, North CarolinaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Atlanta, GeorgiaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Baton Rouge, LouisianaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Burbank, CaliforniaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Canton, OhioHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Champaign, IllinoisHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Chattanooga, TennesseeHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Cincinnati, OhioHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Dallas, TexasHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Dallas, TexasHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Denton, TexasHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Doral, FloridaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- El Paso, TexasHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Farmington Hills, MichiganHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Fayetteville, GeorgiaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Fort Myers, FloridaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Greenville, North CarolinaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Hialeah, FloridaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Hollywood, FloridaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Houston, TexasHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Houston, TexasHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Huntington Beach, CaliforniaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Kansas City, MissouriHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- La Jolla, CaliforniaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Las Vegas, NevadaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Layton, UtahHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Lenexa, KansasHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- McKinney, TexasHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Memphis, TennesseeHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Miami, FloridaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Midlothian, VirginiaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Morehead City, North CarolinaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Morehead City, North CarolinaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Norman, OklahomaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- North Charleston, South CarolinaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Oak Brook, IllinoisHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Oakland, CaliforniaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Orchard Park, New YorkHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Palm Beach Gardens, FloridaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Philadelphia, PennsylvaniaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Raleigh, North CarolinaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- San Antonio, TexasHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- San Diego, CaliforniaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Seattle, WashingtonHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Shavano Park, TexasHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- South Gate, CaliforniaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Springfield, IllinoisHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- St Louis, MissouriHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Statesville, North CarolinaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Tampa, FloridaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Tucson, ArizonaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Walnut Creek, CaliforniaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Washington D.C., District of ColumbiaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Weslaco, TexasHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
- Wilmington, North CarolinaHospital not named in the registryContact: Chief Medical OfficerRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves' disease who are actively hyperthyroid
A vizsgálat 2 csoportja
- BHV-1300A vizsgált kezelés
BHV-1300 is delivered subcutaneously via autoinjector. Participants will be randomized in a 2:1 ratio to receive either BHV-1300 or placebo.
- PlaceboPlacebo, összehasonlításként
Matching placebo is delivered subcutaneously via autoinjector. Participants will be randomized in a 2:1 ratio to receive either BHV-1300 or placebo.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Phase 3, Double-blind, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BHV-1300 in the Treatment of Adults With Graves' Disease
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT07661056: ki vehet részt
- A regiszteradat frissítve
- 2026. november 12.